Skip to content

CARL CARL Net proceeds from sales of subsidiary shares

Net proceeds from sales of subsidiary shares at other companies

Medtronic logo
MedtronicMDT
$134.5M

Other financials

Income statement

See full
Revenue$16.1M+58.2%
Gross profit$12.4M+62.7%
Operating income-$9.3M-62.2%
Net income-$8.7M-51.8%
EPS (diluted)-$0.32+78.2%

Balance sheet

See full
Cash & equivalents$73.0M+68.1%
Total debt$17.3M
Total equity$92.2M+220%
Total assets$118.8M

Cash flow

See full
Operating cash flow-$13.0M-59.5%
CapEx$79.0K-4.8%
Free cash flow-$13.1M-58.8%

Valuation

See full
Market cap$305.56M-20.3%
Enterprise value$249.8M
P/S5.4×

Profitability

See full
Gross margin75.9%+1.4pp
Operating margin-60.5%-10.2pp
Net margin-57.8%-11.2pp
FCF margin-61.1%

Returns & leverage

See full
Return on equity-416.9%
Debt / equity0.2×
Current ratio11.9×

Where this comes from

Reported directly by CARL in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.

The official record: CARL’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about CARL's net proceeds from sales of subsidiary shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CARL's net proceeds from sales of subsidiary shares?
CARL (CARL) reported net proceeds from sales of subsidiary shares of $23.37M in Q4 2025.
What does net proceeds from sales of subsidiary shares mean?
This represents the total cash proceeds received by the company from the sale of its equity securities to the public during an initial public offering. It serves as a primary source of capital for funding operations, research and development, and strategic growth initiatives. This metric is a key indicator of the company's ability to access public capital markets to fuel its business model.